You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluocinolone Acetonide
Accession NumberDB00591  (APRD00977)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionA glucocorticoid derivative used topically in the treatment of various skin disorders. It is usually employed as a cream, gel, lotion, or ointment. It has also been used topically in the treatment of inflammatory eye, ear, and nose disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732). It is also being investigated by Sivida and Alimera, under the brand name Medidur, as a sustained release intraocular implant for the treatment of diabetic macular edema.
Structure
Thumb
Synonyms
6alpha-Fluorotriamcinolone acetonide
6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide
Acetónida de fluocinolona
Acétonide de fluocinolone
Acetonido de fluocinolona
Coriphate
Cortiplastol
Derma-smoothe/fs
Dermalar
Flucinar
Flucort
Fluocet
Fluocinolon acetonid
Fluocinolonacetonid
Fluocinolone 16,17-acetonide
Fluocinoloni acetonidum
Fluonid
Fluotrex
Fluovitif
Flupollon
Fluzon
Iluvien
Jellin
Localyn
Omniderm
Percutina
Prodermin
Radiocin
Retisert
Sinalar
Synalar
Synamol
Synandone
Synandrone
Synemol
Synotic
Synsac
Tefunote
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CapexkitGalderma Laboratories, L.P.1984-10-12Not applicableUs
Capexshampoo0.01 %topicalGalderma Canada Inc2001-02-022014-07-15Canada
Derma Smoothe/fs Liq 0.01%liquid0.01 %topicalHill Dermaceuticals Inc1991-12-31Not applicableCanada
Derma-smoothe/fsoil.11 mg/mLtopicalPhysicians Total Care, Inc.2009-09-03Not applicableUs
Derma-smoothe/fsoil.11 mg/mLtopicalHill Dermaceuticals, Inc.1995-02-162015-12-29Us
Derma-smoothe/fsoil.11 mg/mLtopicalRoyal Pharmaceuticals1995-02-16Not applicableUs
Derma-smoothe/fsoil.11 mg/mLtopicalHill Dermaceuticals, Inc.1988-02-032015-12-29Us
Derma-smoothe/fsoil.11 mg/mLtopicalRoyal Pharmaceuticals1995-02-16Not applicableUs
Dermoticoil.11 mg/mLauricular (otic)Hill Dermaceuticals, Inc.2005-11-092015-12-29Us
Dermoticoil.11 mg/mLauricular (otic)Royal Pharmaceuticals2005-11-09Not applicableUs
Dermotic Oil Ear Dropssolution0.01 %oticHill Dermaceuticals Inc2008-01-09Not applicableCanada
Fluocinolone Acetonidesolution.1 mg/mLtopicalTeligent Pharma, Inc.2012-11-27Not applicableUs
Fluocinolone Acetonideoil.11 mg/mLtopicalSeton Pharmaceuticals2013-08-20Not applicableUs
Fluocinolone Acetonideointment.25 mg/gtopicalIGI Labs, Inc.2012-12-27Not applicableUs
Fluocinolone Acetonideoil.11 mg/mLtopicalSeton Pharmaceuticals2013-08-01Not applicableUs
Fluocinolone Acetonidecream.25 mg/gtopicalIGI Labs, Inc.2012-12-28Not applicableUs
Fluocinolone Acetonidecream.1 mg/gtopicalIGI Labs, Inc.2014-05-15Not applicableUs
Fluocinolone Acetonide 0.01%oil.11 mg/mLauricular (otic)Seton Pharmaceuticals2013-08-01Not applicableUs
Fluoderm Crm 0.01%cream.01 %topicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Fluoderm Crm 0.025%cream.025 %topicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
Fluoderm Ont 0.01%ointment.1 mgtopicalTaro Pharmaceuticals Inc1979-12-312001-08-21Canada
Fluoderm Ont 0.025%ointment0.25 mgtopicalTaro Pharmaceuticals Inc1979-12-31Not applicableCanada
FS Shampoo-0.01%shampoo.01 %topicalHill Dermaceuticals Inc1994-12-312000-11-02Canada
Iluvienimplant.19 mg/1intravitrealAlimera Sciences, Inc.2014-10-15Not applicableUs
Retisertimplant.59 mg/1intravitrealBausch & Lomb Incorporated2005-04-08Not applicableUs
Retisertimplant0.59 mgintravitrealBausch & Lomb Inc2012-09-13Not applicableCanada
Synalarointment.25 mg/gtopicalMedimetriks Pharmaceuticals, Inc.2012-09-27Not applicableUs
SynalarkittopicalMedimetriks Pharmaceuticals, Inc.2012-12-15Not applicableUs
Synalarcream.25 mg/gtopicalMedimetriks Pharmaceuticals, Inc.2012-09-27Not applicableUs
Synalarsolution.1 mg/mLtopicalMedimetriks Pharmaceuticals, Inc.2012-05-31Not applicableUs
SynalarkittopicalMedimetriks Pharmaceuticals, Inc.2012-12-15Not applicableUs
Synalar Cream 0.025%cream0.025 %topicalMedicis Canada Ltd.1970-12-311998-09-25Canada
Synalar Cream Mild 0.01%cream0.01 %topicalMedicis Canada Ltd.1967-12-311998-09-25Canada
Synalar Ointment 0.025%ointment0.025 %topicalValeant Canada Lp/valeant Canada s.e.c.1996-12-31Not applicableCanada
Synalar Ointment Mild 0.01%ointment0.01 %topicalMedicis Canada Ltd.1968-12-311998-09-25Canada
Synalar Ont Regular 0.025%ointment.025 %topicalSyntex Inc.1963-12-311996-09-30Canada
Synalar Solution 0.01%solution0.01 %topicalValeant Canada Lp/valeant Canada s.e.c.1996-12-31Not applicableCanada
Synalar TskitMedimetriks Pharmaceuticals, Inc.2012-08-15Not applicableUs
Synamol Mild 0.01% Creamcream0.01 %topicalMedicis Canada Ltd.1978-12-311998-09-25Canada
Synamol Regular 0.025% Creamcream0.025 %topicalMedicis Canada Ltd.1978-12-311998-09-25Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluocinolone Acetonidecream.25 mg/gtopicalG&W Laboratories, Inc.2013-12-20Not applicableUs
Fluocinolone Acetonidecream.1 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1982-12-16Not applicableUs
Fluocinolone Acetonidesolution.1 mg/mLtopicalPhysicians Total Care, Inc.1996-04-03Not applicableUs
Fluocinolone Acetonideoil.11 mg/118.28mLtopicalAv Kare, Inc.2013-12-17Not applicableUs
Fluocinolone Acetonidecream.25 mg/gtopicalG&W Laboratories, Inc.1988-07-26Not applicableUs
Fluocinolone Acetonideoil.11 mg/118.28mLtopicalAmneal Pharmaceuticals, LLC2015-09-22Not applicableUs
Fluocinolone Acetonidecream.1 mg/gtopicalSTAT Rx USA LLC1982-12-16Not applicableUs
Fluocinolone Acetonidesolution.1 mg/mLtopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1982-12-16Not applicableUs
Fluocinolone Acetonideoil.11 mg/118.28mLtopicalPhysicians Total Care, Inc.2012-04-26Not applicableUs
Fluocinolone Acetonidesolution.1 mg/mLtopicalGAVIS Pharmaceuticals, LLC2015-09-02Not applicableUs
Fluocinolone Acetonidecream.1 mg/gtopicalG&W Laboratories, Inc.1988-07-26Not applicableUs
Fluocinolone Acetonideoil.11 mg/118.28mLtopicalAmneal Pharmaceuticals, LLC2015-09-22Not applicableUs
Fluocinolone Acetonideoil.11 mg/20mLauricular (otic)Av Kare, Inc.2013-12-18Not applicableUs
Fluocinolone Acetonidecream.25 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1982-12-16Not applicableUs
Fluocinolone Acetonideoil.11 mg/118.28mLtopicalPhysicians Total Care, Inc.2012-12-07Not applicableUs
Fluocinolone Acetonidesolution.1 mg/mLtopicalTaro Pharmaceuticals U.S.A., Inc.2015-03-27Not applicableUs
Fluocinolone Acetonideointment.25 mg/gtopicalG&W Laboratories, Inc.1988-07-26Not applicableUs
Fluocinolone Acetonideoil.11 mg/118.28mLtopicalAv Kare, Inc.2013-12-17Not applicableUs
Fluocinolone Acetonideointment.25 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1982-12-16Not applicableUs
Fluocinolone Acetonideoil.11 mg/20mLauricular (otic)Amneal Pharmaceuticals, LLC2015-09-22Not applicableUs
Fluocinolone Acetonidecream.1 mg/gtopicalA S Medication Solutions Llc1982-12-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DermalarTeva
FlucinarJelfa
FluonidBiolab
FlupollonMayado Seiyaku
FutocanShinlon
JellinGrünenthal
LocafluoRecordati
MeclodermICI
Brand mixtures
NameLabellerIngredients
Neo-synalarMedimetriks Pharmaceuticals
Synalar Bi-otic SolutionMedicis Canada Ltd.
Tri-lumaGalderma Laboratories, L.P.
SaltsNot Available
Categories
UNII0CD5FD6S2M
CAS number67-73-2
WeightAverage: 452.4882
Monoisotopic: 452.201045102
Chemical FormulaC24H30F2O6
InChI KeyInChIKey=FEBLZLNTKCEFIT-VSXGLTOVSA-N
InChI
InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)CO
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Meta-dioxolane
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert).
PharmacodynamicsNot Available
Mechanism of actionFluocinolone Acetonide is a corticosteroid that binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver.
Related Articles
AbsorptionRapidly absorbed (15 minutes)
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily hepatic, corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Half life1.3-1.7 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9865
Blood Brain Barrier+0.9683
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7912
P-glycoprotein inhibitor INon-inhibitor0.5674
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8304
CYP450 2C9 substrateNon-substrate0.8679
CYP450 2D6 substrateNon-substrate0.8856
CYP450 3A4 substrateSubstrate0.6964
CYP450 1A2 substrateNon-inhibitor0.9327
CYP450 2C9 inhibitorNon-inhibitor0.9394
CYP450 2D6 inhibitorNon-inhibitor0.9559
CYP450 2C19 inhibitorNon-inhibitor0.9311
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8806
Ames testNon AMES toxic0.7682
CarcinogenicityNon-carcinogens0.9174
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7033 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9838
hERG inhibition (predictor II)Non-inhibitor0.671
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alpharma us pharmaceuticals division
  • E fougera div altana inc
  • G and w laboratories inc
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Taro pharmaceuticals inc
  • Taro pharmaceuticals usa inc
  • Usl pharma inc
  • Allergan herbert div allergan inc
  • Savage laboratories inc div altana inc
  • Medicis pharmaceutical corp
  • Bausch and lomb inc
  • Hill dermaceuticals inc
  • Galderma laboratories lp
  • Bausch and lomb pharmaceuticals inc
  • Morton grove pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Kit
Shampootopical0.01 %
Liquidtopical0.01 %
Solutionotic0.01 %
Creamtopical.1 mg/g
Creamtopical.25 mg/g
Oilauricular (otic).11 mg/20mL
Oiltopical.11 mg/118.28mL
Oiltopical.11 mg/mL
Ointmenttopical.25 mg/g
Solutiontopical.1 mg/mL
Oilauricular (otic).11 mg/mL
Creamtopical.01 %
Creamtopical.025 %
Ointmenttopical.1 mg
Ointmenttopical0.25 mg
Shampootopical.01 %
Implantintravitreal.19 mg/1
Kit
Implantintravitreal.59 mg/1
Implantintravitreal0.59 mg
Kittopical
Solutionotic
Creamtopical0.025 %
Ointmenttopical0.025 %
Ointmenttopical0.01 %
Ointmenttopical.025 %
Solutiontopical0.01 %
Creamtopical0.01 %
Creamtopical
Prices
Unit descriptionCostUnit
Retisert implant21900.0USD each
Synalar 0.01% Solution 60ml Bottle108.72USD bottle
Synalar 0.025% Cream 60 gm Tube103.1USD tube
Synalar 0.025% Ointment 60 gm Tube103.1USD tube
Fluocinolone Acetonide 0.01% Cream 15 gm Tube76.61USD tube
Fluocinolone Acetonide 0.01% Cream 60 gm Tube73.5USD tube
Fluocinolone Acetonide 0.025% Cream 15 gm Tube46.1USD tube
Fluocinolone Acetonide 0.025% Cream 60 gm Tube38.99USD tube
Fluocinolone Acetonide 0.025% Ointment 60 gm Tube38.99USD tube
Fluocinolone acetonide powder35.28USD g
Fluocinolone Acetonide 0.025% Ointment 15 gm Tube33.47USD tube
Fluocinolone Acetonide 0.01% Solution 60ml Bottle20.45USD bottle
Dermotic oil 0.01% ear drops1.75USD ml
Derma-smoothe-fs scalp oil0.35USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6217895 No1999-03-222019-03-22Us
US6375972 No2000-04-262020-04-26Us
US6548078 No1999-03-222019-03-22Us
US7915243 No2006-03-222026-03-22Us
US7939516 No2005-05-042025-05-04Us
US8247395 No2002-10-222022-10-22Us
US8252307 No1999-06-272019-06-27Us
US8653053 No2002-10-252022-10-25Us
US8871241 No2007-08-122027-08-12Us
US8932610 No2010-03-242030-03-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point266-268Mills, J.S. and Bowers, A.; U.S. Patent 3,014,938; December 26, 1961; assigned to Syntex SA, Mexico.
logP2.48HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0547 mg/mLALOGPS
logP2.47ALOGPS
logP1.6ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.35ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity111.41 m3·mol-1ChemAxon
Polarizability44.97 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Mills, J.S. and Bowers, A.; U.S. Patent 3,014,938; December 26, 1961; assigned to Syntex SA, Mexico.

General References
  1. Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, Usner DW, Comstock TL: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007 Nov;125(11):1478-85. Epub 2007 Oct 8. [PubMed:17923537 ]
  2. Brumm MV, Nguyen QD: Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64. [PubMed:17722513 ]
  3. Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P: Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75. [PubMed:11006254 ]
External Links
ATC CodesS02BA08S01BA15S01CA10S02CA05D07CC02D07BC02D07AC04C05AA10
AHFS Codes
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (49.7 KB)
MSDSDownload (75.1 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluocinolone Acetonide.
AldesleukinFluocinolone Acetonide may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluocinolone Acetonide.
AmiodaroneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Amiodarone.
Amphotericin BFluocinolone Acetonide may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluocinolone Acetonide.
BazedoxifeneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Bazedoxifene.
BendroflumethiazideFluocinolone Acetonide may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluocinolone Acetonide.
Bismuth SubcitrateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Boceprevir.
BumetanideFluocinolone Acetonide may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocinolone Acetonide.
Calcium carbonateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Carbamazepine.
CeritinibFluocinolone Acetonide may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ceritinib.
ChlorothiazideFluocinolone Acetonide may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneFluocinolone Acetonide may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Fluocinolone Acetonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocinolone Acetonide.
CoumaphosThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Coumaphos.
DarunavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Dichlorvos.
DienestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinolone Acetonide.
DihydrotestosteroneFluocinolone Acetonide may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Edrophonium.
EnzalutamideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estriol.
EstroneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estrone.
Etacrynic acidFluocinolone Acetonide may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Fenthion.
FluoxymesteroneFluocinolone Acetonide may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Fosphenytoin.
FurosemideFluocinolone Acetonide may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluocinolone Acetonide.
HexestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinolone Acetonide.
HydrochlorothiazideFluocinolone Acetonide may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideFluocinolone Acetonide may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Fluocinolone Acetonide.
IndapamideFluocinolone Acetonide may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluocinolone Acetonide.
ItraconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocinolone Acetonide.
MestranolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Mestranol.
MethyclothiazideFluocinolone Acetonide may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneFluocinolone Acetonide may increase the fluid retaining activities of Methyltestosterone.
MetolazoneFluocinolone Acetonide may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Fluocinolone Acetonide can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Minaprine.
MitotaneThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.
NefazodoneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Neostigmine.
NevirapineThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Nicorandil.
OxandroloneFluocinolone Acetonide may increase the fluid retaining activities of Oxandrolone.
OxymetholoneFluocinolone Acetonide may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluocinolone Acetonide.
PhenytoinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Physostigmine.
PiretanideFluocinolone Acetonide may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Polyestradiol phosphate.
PolythiazideFluocinolone Acetonide may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pyridostigmine.
QuinestrolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Quinestrol.
QuinethazoneFluocinolone Acetonide may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluocinolone Acetonide.
RifabutinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluocinolone Acetonide.
SaquinavirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Fluocinolone Acetonide.
StanozololFluocinolone Acetonide may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluocinolone Acetonide.
TelaprevirThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Telithromycin.
TestosteroneFluocinolone Acetonide may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Tibolone.
TorasemideFluocinolone Acetonide may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Trichlorfon.
TrichlormethiazideFluocinolone Acetonide may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Tubocurarine.
VoriconazoleThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Voriconazole.
WarfarinFluocinolone Acetonide may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58. [PubMed:19744340 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Phospholipase a2 activity
Specific Function:
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:
PLA2G4A
Uniprot ID:
P47712
Molecular Weight:
85238.2 Da
References
  1. Norris JF, Ilderton E, Yardley HJ, Summerly R, Forster S: Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203. [PubMed:6743552 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 03:11